

## II. CLAIM AMENDMENTS

1. (Currently Amended) An abuse-proofed, thermoformed dosage form containing, ~~in addition to~~

one or more active ingredients with abuse potential (A) selected from the group consisting of opiates and opioids,

~~optionally together with~~ physiologically acceptable auxiliary substances (B),

at least one synthetic or natural polymer (C) comprising a polyalkylene oxide having a molecular weight of at least 0.5 million according to rheological measurements, and

optionally at least one wax (D),

wherein component (C) is present in quantities such that the dosage form has a breaking strength of at least 500 N and wherein the active ingredient with abuse potential (A) is present in a controlled release matrix of component (C).

2. (Currently Amended) ~~[[A]]~~ The dosage form according to claim 1, which is in the form of a tablet.

3. Cancelled

4. (Currently Amended) ~~[[A]]~~ The dosage form according to claim 1, wherein the polymer (C) is at least one polymer selected from the group consisting of polyethylene oxide, polymethylene oxide, polypropylene oxide, ~~polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, polyacrylate~~ copolymers and the mixtures thereof.

5. Cancelled

6. (Currently Amended) ~~[[A]]~~ The dosage form according to ~~claim 5~~ claim 1, wherein the molecular weight of component (C) is 1-15 million.

7. (Currently Amended) ~~[[A]]~~ The dosage form according to claim 1, wherein the wax (D) is at least one natural, semi-synthetic or synthetic wax with a softening point of at least 60°C.

8. (Currently Amended) ~~[[A]]~~ The dosage form according to claim 7, wherein the wax (D) is carnauba wax or beeswax.

9 - 26. Cancelled

27. (Currently Amended) A process for the production of a dosage form according to claim 1, wherein components (A), the optionally present component (B), component (C) and the optionally present component (D) ~~and the optionally present components (a) to (f)~~ are mixed, and the resultant mixture, optionally after granulation, is press-formed to yield the dosage form with preceding or simultaneous, ~~or subsequent~~ exposure to heat.

28. (Currently Amended) ~~[[A]]~~ The process according to claim 27, wherein granulation is performed by means of a melt process.

29. (Currently Amended) ~~[[A]]~~ The dosage form according claim 1 obtainable by a process wherein components (A), the optionally present component (B), component (C) and the optionally present component (D) ~~and the optionally present components (a) to (f)~~ are mixed, and the resultant mixture, optionally after granulation, is press-formed to yield the dosage form with preceding; or simultaneous, ~~or subsequent~~ exposure to heat.

30. (Cancelled)

31. (Currently Amended) ~~[[A]]~~ The dosage form according to claim 4, wherein polymer (C) is polyethylene oxide.

USSN 10/718,112  
Office Action dated December 28, 2006  
Attorney Docket: 785-011574-US (C01)

32-40. Cancelled